ECM
CMPX icon

Element Capital Management’s Compass Therapeutics CMPX Stock Holding History

Element Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-293,888
Closed -$458K – 58
2023
Q4 		$458K Buy
+293,888
New +$509K 1.55% 9

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Element Capital Management's CMPX Position: Q1 2024 in Review

Element Capital Management sold out of Compass Therapeutics (CMPX) in Q1 2024, closing a stake of 293,888 shares — an estimated $458K sold.

Element Capital Management first reported a position in CMPX in Q4 2023 and held it in 1 quarter. The position peaked at $458K in Q4 2023. 78 funds tracked by Wall St. Rank hold CMPX as of Q1 2024.

  • Element Capital Management reported no remaining Compass Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Element Capital Management sold 293,888 Compass Therapeutics shares in Q1 2024, an estimated $458K.
  • Element Capital Management first reported a position in Compass Therapeutics in Q4 2023 and held it in 1 quarter.
  • Element Capital Management's Compass Therapeutics position peaked at $458K in Q4 2023.
  • 78 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2024.

Based on Element Capital Management's 13F filing for Q1 2024, filed 9 May 2024.